Zealand Pharma A/S had revenue of DKK 6.6 million (€0.9 million) for 2013, wholly made up of royalty payments on sales of its first marketed product, Lyxumia (lixisenatide), for Type 2 diabetes. Revenue in 2012 was DKK 223.6 million and milestone based.
